Human Epidermal Growth Factor 2 (HER2) Non-Small Cell Lung Cancer (NSCLC) with YVMA Mutation Responsive to Ado-Trastuzumab Emtansine

reportActive / Technical Report | Accesssion Number: AD1084259 | Open PDF

Abstract:

Human epidermal growth factor 2/NEU (HER2) aberrations account for 4.7-10% of all non-small cell lung cancers (NSCLC), making it one of the more prevalent forms of NSCLC. HER2 aberrations also instigate breast cancer and these patients commonly demonstrate a robust response to HER targeted immunotherapies. This optimistically promised that HER2 NSCLC might also respond via the same pathophysiologic mechanisms. To date, this promise has largely failed to deliver and an early trial ended in cancellation due to lack of efficacy. Contrary to this lack of efficacy, this case presents a patient with HER2 positive NSCLC with a specific gene amplification that demonstrated response to HER2 therapy. This adds to the growing evidence that targeted therapy can be efficacious in some HER2 positive NSCLC. It further reinforces the need for extended mutational testing in lung cancer patients, particularly those with a smoking history.

Author(s):
Stoll, Kristin E.
Author Organization(s):
59th Medical Wing
Funding Organization(s):
Publication Date:
2019 Jul 08
Pagination:
0

Security Markings

RECORD

Collection: TRECMS
Subject Terms
Communities of Interest:
Biomedical
Descriptor(s):
oncology, breast cancer, growth factors, lung cancer, neoplasms, clinical trials, genetic testing, cancer, disease attributes, diseases and disorders, proteins, therapy, amplification, internet, mutations, x-ray computed tomography, air force
Keyword(s):
her2(Human epidermal growth factor 2), nsclc(non-small cell lung cancers), ct(computed tomography)
Subject Categories:
Biological and Medical Sciences; Biological and Medical Sciences
Update Date:
2019 Dec 19